Popular Qt-Prolonging Drugs In Oncology And Their Names

by

In the field of oncology, managing the side effects of cancer treatments is crucial for patient safety and quality of life. One significant concern is the prolongation of the QT interval, a measure of electrical activity in the heart’s ventricles. Certain drugs used in cancer therapy can cause QT prolongation, which may lead to serious arrhythmias such as Torsades de Pointes.

Understanding QT Prolongation

The QT interval appears on an electrocardiogram (ECG) and represents the time it takes for the heart’s ventricles to depolarize and repolarize. When this interval is extended beyond normal limits, it increases the risk of irregular heartbeats. Certain medications can interfere with the electrical activity of the heart, leading to QT prolongation.

Common Oncology Drugs That Prolong the QT Interval

  • Arsenic Trioxide – Used in acute promyelocytic leukemia (APL)
  • Tyrosine Kinase Inhibitors – Such as Dasatinib, Nilotinib, and Lapatinib
  • Hedgehog Pathway Inhibitors – Including Vismodegib and Sonidegib
  • Antiemetics – Like Ondansetron and Dolasetron
  • Proteasome Inhibitors – Such as Bortezomib

Specific Drugs and Their Names

Below is a list of some of the most commonly used QT-prolonging drugs in oncology, along with their generic and brand names where applicable.

  • Arsenic Trioxide – Brand name: Trisenox
  • Dasatinib – Brand name: Sprycel
  • Nilotinib – Brand name: Tasigna
  • Lapatinib – Brand name: Tykerb
  • Vismodegib – Brand name: Erivedge
  • Sonidegib – Brand name: Odomzo
  • Ondansetron – Brand name: Zofran
  • Dolasetron – Brand name: Anzemet
  • Bortezomib – Brand name: Velcade

Monitoring and Management

Patients receiving these medications should be closely monitored with regular ECGs to detect QT prolongation early. Dose adjustments or discontinuation may be necessary if significant prolongation occurs. Additionally, correcting electrolyte imbalances, such as hypokalemia or hypomagnesemia, can help reduce the risk of arrhythmias.

Conclusion

Awareness of the QT-prolonging potential of certain oncology drugs is essential for healthcare providers. Proper monitoring and management strategies can mitigate risks, ensuring safer cancer treatment protocols and better patient outcomes.